Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

The company abandons TNG908, but is still all in on the troubled target.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.